Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.